Surgeons and oncologists within the Department of Surgery at Penn Medicine are using adjuvant hepatic artery infusion (HAI) chemotherapy with systemic chemotherapy to prevent recurrence in patients with resected colorectal liver metastases (CLMs) or to treat unresectable CLMs.

The liver is both the most common site for CLMs to occur and the most common site of CLM recurrence following resection and chemotherapy, the mainstays of treatment for colon cancer metastases to the liver.